UK media reporting of NICE recommendation of crizanlizumab for patients with sickle cell disease

Richard Buka; Noemi Roy; Pip Nicolson

doi:10.1002/jha2.623

UK media reporting of NICE recommendation of crizanlizumab for patients with sickle cell disease

Richard Buka^*, Noemi Roy, Pip Nicolson

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

42 Downloads (Pure)

Abstract

Crizanlizumab was recommended for use in patients with sickle cell disease in the UK in October 2021 and received widespread media coverage. Accuracy of reporting is paramount in building trust with this group of patients who are often wary of the medical profession. We carried out an analysis of internet-based news articles and applied a validated scoring system to assess quality. 21 articles from 19 media organisations were identified. 71% of articles stated unproven benefits of the drug and only 14% were of satisfactory quality. The former was largely due to quoting of two NHS England press releases. Overstating of drug efficacy may be detrimental to the need to address healthcare inequalities.

Original language	English
Number of pages	5
Journal	EJHaem
Early online date	25 Dec 2022
DOIs	https://doi.org/10.1002/jha2.623
Publication status	E-pub ahead of print - 25 Dec 2022

Keywords

Crizanlizumab
Sickle cell disease
Media

Access to Document

10.1002/jha2.623Licence: Creative Commons: Attribution (CC BY)

BukaR2022UKmediaFinal published version, 427 KBLicence: Creative Commons: Attribution (CC BY)

Cite this

@article{33e657c1be844a97a3828cbc65f75d51,

title = "UK media reporting of NICE recommendation of crizanlizumab for patients with sickle cell disease",

abstract = "Crizanlizumab was recommended for use in patients with sickle cell disease in the UK in October 2021 and received widespread media coverage. Accuracy of reporting is paramount in building trust with this group of patients who are often wary of the medical profession. We carried out an analysis of internet-based news articles and applied a validated scoring system to assess quality. 21 articles from 19 media organisations were identified. 71% of articles stated unproven benefits of the drug and only 14% were of satisfactory quality. The former was largely due to quoting of two NHS England press releases. Overstating of drug efficacy may be detrimental to the need to address healthcare inequalities.",

keywords = "Crizanlizumab, Sickle cell disease, Media",

author = "Richard Buka and Noemi Roy and Pip Nicolson",

year = "2022",

month = dec,

day = "25",

doi = "10.1002/jha2.623",

language = "English",

journal = "EJHaem",

issn = "2688-6146",

publisher = "Wiley",

}

TY - JOUR

T1 - UK media reporting of NICE recommendation of crizanlizumab for patients with sickle cell disease

AU - Buka, Richard

AU - Roy, Noemi

AU - Nicolson, Pip

PY - 2022/12/25

Y1 - 2022/12/25

N2 - Crizanlizumab was recommended for use in patients with sickle cell disease in the UK in October 2021 and received widespread media coverage. Accuracy of reporting is paramount in building trust with this group of patients who are often wary of the medical profession. We carried out an analysis of internet-based news articles and applied a validated scoring system to assess quality. 21 articles from 19 media organisations were identified. 71% of articles stated unproven benefits of the drug and only 14% were of satisfactory quality. The former was largely due to quoting of two NHS England press releases. Overstating of drug efficacy may be detrimental to the need to address healthcare inequalities.

AB - Crizanlizumab was recommended for use in patients with sickle cell disease in the UK in October 2021 and received widespread media coverage. Accuracy of reporting is paramount in building trust with this group of patients who are often wary of the medical profession. We carried out an analysis of internet-based news articles and applied a validated scoring system to assess quality. 21 articles from 19 media organisations were identified. 71% of articles stated unproven benefits of the drug and only 14% were of satisfactory quality. The former was largely due to quoting of two NHS England press releases. Overstating of drug efficacy may be detrimental to the need to address healthcare inequalities.

KW - Crizanlizumab

KW - Sickle cell disease

KW - Media

UR - https://onlinelibrary.wiley.com/journal/26886146

U2 - 10.1002/jha2.623

DO - 10.1002/jha2.623

M3 - Article

SN - 2688-6146

JO - EJHaem

JF - EJHaem

ER -

UK media reporting of NICE recommendation of crizanlizumab for patients with sickle cell disease

Abstract

Keywords

Access to Document

Fingerprint

Cite this